Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027. This expansion is underpinned by several significant factors, including the escalating volume of surgeries, a surge in trauma and road accidents, and an increasing prevalence of chronic conditions such as cancer.

A host of other factors driving market growth encompass growing awareness about the criticality of blood donations, a substantial patient pool, governmental initiatives, amplified investments in research and development endeavors, diverse blood donation campaigns conducted by organizations, a rise in the aging population, increased research and technological advancements. Strategic initiatives including partnerships and product launches undertaken by market players further contribute to market growth.

Trauma and Road Accidents Amplifying Demand

The rise in trauma and road accidents is a pivotal driver of market growth. Instances of hemorrhage, resulting in a reduction of blood volume that the body cannot rapidly replace, propel the demand for blood or plasma transfusion. In the U.S., an estimated 60,000 deaths annually in 2018 were attributed to hemorrhage. Additionally, escalating road accidents contribute to excessive blood loss, necessitating blood or plasma transfusion to counteract bleeding. The increasing occurrence of these situations significantly bolsters the global blood and plasma component market. According to WHO, nearly 1.5 million individuals succumbed to road traffic injuries globally in 2020.

Rising Blood Disorders and Surgical Interventions

Increasing instances of bleeding disorders and the growing number of surgeries worldwide fuel market expansion. Hemophilia A, B, and von Willebrand disease constitute prevalent bleeding disorders. Hemophilia diagnoses globally totaled 195,263 in 2019, alongside 80,302 cases of von Willebrand disease. Moreover, surging surgical procedures contribute to market growth due to substantial blood loss during operations, thereby elevating the demand for transfusions. This need further extends to anemic patients. The global landscape witnesses approximately 310 million major surgeries annually, with 50 million in the USA and 20 million in Europe.

Inorganic Growth Strategies Drive Progress

The adoption of inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships significantly propels market growth. Notable instances include the collaboration between the Blood Center of Wisconsin and SysLogic Inc., researching RFID technology for enhanced patient safety during blood collection and transfusion. In 2018, Invitrx Inc. launched a cord blood plasma product containing plasticity-promoting proteins, potentially eliciting anti-aging effects that promote neurogenesis and cognitive function.

Market Segmentation and Influential Players

The global blood & plasma components market is categorized based on products, applications, end-users, and companies. Product divisions encompass packed red blood cells, platelet products, frozen plasma, and plasma-derived products. The latter are further classified into immunoglobulins, albumins, coagulation factor concentrates, and more. Applications span hematology, solid tumor management, and others, with hematology subcategories including hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and more. End-users encompass hospitals & clinics, diagnostic laboratories, and others. Geographically, the United States is poised as a robust market due to the surge in chronic diseases and surgeries.

Market Leaders Shaping the Landscape

Prominent companies steering the blood & plasma components market include CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. These industry leaders contribute significantly to the market's growth trajectory.

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Blood & Plasma Components Market

5. Voice of Customer

6. Global Blood & Plasma Components Market Outlook

7. North America Blood & Plasma Components Market Outlook

8. Europe Blood & Plasma Components Market Outlook

9. Asia-Pacific Blood & Plasma Components Market Outlook

10. South America Blood & Plasma Components Market Outlook

11. Middle East and Africa Blood & Plasma Components Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Competitive Landscape

15. Strategic Recommendations

A selection of companies mentioned in this report includes:

• CSL Limited
• Grifols S.A.
• ADMA Biologics, Inc.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A.
• Emergent BioSolutions Inc.
• Bio Products Laboratory Ltd.
• LFB S.A.
• Versiti, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/p3ggss

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.